Skip to main content
Premium Trial:

Request an Annual Quote

Applied BioCode, Genetic Analysis Ink Licensing Agreement

NEW YORK (GenomeWeb News) – Applied BioCode today said it has signed a license and supply agreement covering its barcoded magnetic bead (BMB) technology with molecular diagnostics firm Genetic Analysis.

The deal, which covers in vitro diagnostic and life science research applications, gives Genetic Analysis access to BMB patents and BioCode analyzers for molecular diagnostic testing of microbial imbalances in the gastrointestinal tract. Further details of the agreement were not disclosed.

Genetic Analysis, based in Oslo, Norway, launched its first product, the GA-map IBS Dysbiosis Test in October. GA-map is a DNA-based platform technology that allows for the simultaneous analysis of a large number of similar gene fragments in one reaction, it said on its website.

"Our barcoded magnetic beads and BioCode multiplex analyzers along with Genetic Analysis's GA-map IBS Dysbiosis Test will enable researchers and healthcare providers access to new ways to address this sometime[s] debilitating disease," Applied BioCode President Winston Ho said in a statement.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more